Related Experiment Videos
Effect of clonidine in obstructive sleep apnea
1Faculty of Medicine, University of Calgary, Alberta, Canada.
The American Review of Respiratory Disease
|February 1, 1992
Summary
Clonidine hydrochloride, an alpha 2-adrenergic agonist, improved nocturnal hypoxemia in obstructive sleep apnea patients by suppressing REM sleep. However, it did not affect non-REM breathing issues.
Area of Science:
- Sleep Medicine
- Pharmacology
Background:
- Continuous positive airway pressure is the primary treatment for obstructive sleep apnea (OSA).
- Patient tolerance to continuous positive airway pressure can be a significant issue.
Purpose of the Study:
- To evaluate the effects of clonidine hydrochloride on sleep patterns and breathing in male patients with OSA.
- To assess clonidine's potential as an alternative or adjunctive therapy for OSA.
Main Methods:
- Eight male OSA patients underwent polysomnography during a 10-day clonidine hydrochloride treatment course.
- Sleep-stage distribution and breathing patterns were compared between clonidine, placebo, and control nights.
Main Results:
- Clonidine hydrochloride (0.2 mg) suppressed REM sleep in two patients and reduced REM sleep duration in six others.
- Nocturnal hypoxemia improved in six patients, attributed to REM sleep suppression or altered breathing patterns during REM.
- Clonidine did not impact non-REM breathing abnormalities.
Conclusions:
- Clonidine hydrochloride demonstrates potential in managing nocturnal hypoxemia associated with OSA, particularly through REM sleep modulation.
- Further research is warranted to explore clonidine's efficacy and safety profile in a broader OSA patient population.